Toshio Imai

6PUBLICATIONS
56CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical devicesAutoimmunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 10, 2024
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium.

Jason W-L Eng, Yu Kato, Yusuke Adachi

|Oct 24, 2022
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs.

Shuntaro Tsukamoto, Naoko Hata Sugi, Kyoko Nishibata

|Oct 17, 2022
The Fractalkine-CX3CR1 Axis Regulates Non-inflammatory Osteoclastogenesis by Enhancing Precursor Cell Survival.

Yoshikazu Kuboi, Yukiko Kuroda, Masayoshi Ohkuro

|Apr 30, 2021
Serum APOA4 Pharmacodynamically Represents Administered Recombinant Human Hepatocyte Growth Factor (E3112).

Sotaro Motoi, Mai Uesugi, Takashi Obara

|Nov 12, 2020
Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases.

Yoshiya Tanaka, Kana Hoshino-Negishi, Yoshikazu Kuboi

|Oct 10, 2020
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study.

Yoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka

Pageof 1

Frequent Collaborators

2 joint publications

Yoshiya Tanaka

2 joint publications

Junji Matsui

2 joint publications

Yu Kato

2 joint publications

Youya Nakazawa